Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Artificial pancreas device system market is undergoing steady dynamics due to advances in technology, growing diabetes prevalence, and intense focus on the method of administering insulin. Technological innovation is a principal force that determines the patterns of competition in the pancreas device system market. These systems, also called as closed-loop systems, attempt to automate and perfect insulin delivery responding to real-time glucose levels that offer giving individuals with diabetes an enhanced control over their blood sugar levels. The presence of a CGM along with an insulin pump in the basic design of artificial pancreas system provides added precision and a better control of the glucose level.
Rising cases of diabetes, especially type 1 diabetes, is the key factor behind the development of markets for artificial pancreas device systems. The global increase in diabetes rates leads to a direct need for innovative technologies, which can be used to improve the process of insulin administration. Artificial pancreas systems have the advantage of a more systematic and automated administering of insulin. with the result that individuals with diabetes can be relieved of the burden of self-managing their diabetes and also of having unchecked diabetes.
Regulation lends a hand greatly in influencing how the man-made pancreas device system market will work. Stringent regulations and standards warrant that these medical devices that offer brand-new medicine ways are safe and effective, and of good quality. Compliance with regulatory requirements becomes an obligatory factor for approval of the products in the market, for increasing confidence among health professionals and patients, and to ensure the acceptance of the artificial pancreas system among general population.
The artificial pancreas devices system market dynamics are also driven by the shift from conventional diabetes care to patient-oriented and personalized treatments. As part of the bigger picture of diabetes self-care, the user-centered interface, connectivity features and data sharing function of these systems are key enablers in empowering people with diabetes to actively manage their condition. Artificial pancreas systems provide clarity of what's going on with glucose levels of an individual, making it possible to react timely and adjust adequately to prevent hypoglycemia and hyperglycemia.
The healthcare market dynamics also evolve in accordance with the economic conditions or reimbursement policies. The consideration of low cost and availability of artificial pancreas systems makes many people with diabetes and healthcare providers to accept them. Compendious repayment policies have consequences on product acceptance, use and market behavior at the global level. It is imperative for the economic sustainability of artificial pancreas programming for them to get the widespread adoption and the availability.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Segment Outlook | Type, End User and Region |
Artificial Pancreas Device System Market Highlights:
Global Artificial Pancreas Device System Market Overview
The Artificial Pancreas Device System Market size is anticipated to reach USD 0.4 billion by 2032 at 17% CAGR during the forecast period 2023-2032.The need for artificial pancreas devices has recently surged as the number of instances involving pancreatic diseases and malfunctions has climbed significantly. The increasing number of diabetes patients detected is a crucial driver in encouraging market expansion.
The increased infusion of investment into the industry is predicted to improve product quality, hence increasing market sales. Patients are more involved in the selection of their treatment alternatives in some circumstances now that they are more or less aware of the treatment possibilities. This aspect is expected to favorably impact the growth of the artificial pancreas device system market over the forecast period.
Artificial Pancreas Device System Market Trends
The market perspective offered by MRFR spans the entire market and gives in-depth coverage of the latest trends that are shaping the future of the artificial pancreas device system market. The report aptly captures the development of the market through current market trends, historical growth analysis, and revenue projections for a period ranging to 2023. The market also mentions CTR (Control to Range) Systems and CTT (Control to Target) Systems. The end user segments such as hospital and medical centers are also significantly emphasized upon, and a detailed analysis of the segments is also presented in the report. The market dynamics related to pricing and feasibility analysis is significantly along with macroeconomic indicators, and feasibility indicators provides a comprehensive overview of the artificial pancreas device system market in the forecast period.
The report on the artificial pancreas device system market consists of market dynamics, forecast, historical market trends, market value by region as well as by country-level analysis for each market segment, segmentation, market factor analysis and key player’s market share analysis that includes supply chain and Porter’s five forces analysis of the market.
Key Companies in the market of artificial pancreas device system include
- Medtronic Plc
- Bigfoot Biomedical
- Johnson & Johnson
- Dexcom Inc.
- Cellnovo
- Tandem Diabetes Care Inc.
- Pancreum Inc.
- TypeZero Technologies LLC
- Beta Bionics
- F. Hoffmann-La Roche Ltd
- Inreda Diabetic B.V.
- Insulet Corp
Research Methodology
The progression of research while creating reports at Market Research Future includes highlights and facts that are essential to the expansion of artificial pancreas device system market. The research initiated by our analysts enhances the capability of our clients to outline their vision for growth better. The unification of primary and secondary research approaches in our reports divulges widespread information connected to new revenue pockets and developing markets globally. The report methodology also ensures strategy roadmaps that exhibit a distinct picture of the present trends as well as the trends that can affect the forthcoming development of the artificial pancreas device system market. An intrinsic level of understanding connected to the value chain in a specific market additionally contributes to the value of the reports created by our analysts. Furthermore, the insights into markets, technologies, and industry sectors is positively achieved by the application of top-down and bottom-up approaches.
Artificial Pancreas Device System Industry Developments
In october 2023,
Medtronic received FDA approval for their MiniMed 780G system, a hybrid closed-loop system with features like automated basal rate adjustments and mealtime bolusing suggestions.
In November 2023,
Dexcom received FDA approval for their G7 continuous glucose monitoring (CGM) system, featuring a smaller sensor and improved accuracy.
Bigfoot Biomedical is a medical device business that is revolutionizing diabetes care for patients who require insulin. The business is working on an end-to-end type 1 diabetes management system that employs a simple design, cloud connection, and human-centered automation. It improves insulin administration and delivery via an integrated medical device ecosystem powered by machine learning and augmented by secure, user-friendly consumer technology, radically altering the care paradigm.
Tandem Diabetes Care Inc (Tandem) is a medical device manufacturer that creates diabetes care devices. The t: slim X2 insulin pump, basal-IQ technology, Control-IQ technology, software and apps, infusion sets, and various pump accessories are all part of the company's product line. It also provides linked health services. It also offers product support services to assist its customers in further customizing their systems. The firm sells its products in almost all the countries such as Australia, New Zealand, South Africa, France, and Germany. Tandem's headquarters are in San Diego, California, USA.
Artificial Pancreas Device System Market Segmentation
The segmentation of the artificial pancreas device market has been carried out to better gauge the artificial pancreas device system market.
Artificial Pancreas Device System Type Outlook
- CTR (Control to Range) Systems
- CTT (Control To Target) Systems
Artificial Pancreas Device System End User Outlook
- Hospitals
- Medical Centers
Artificial Pancreas Device System Region Outlook
- North America
- South America
- Europe
- Asia-Pacific
- Middle East
- Africa
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
